|
Synonyms: RG-7221 | RG7221 | RO5520985
Compound class:
Antibody
Comment: Vanucizumab is an investigational bi-specific monoclonal antibody, with potential anti-neoplastic activity being developed by Hoffmann-La Roche [1-2]. Vanucizumab simultaneously targets angiopoietin 2 (ANGPT2) and vascular endothelial growth factor A (VEGFA).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST seuqence analysis reveals 100% matches with peptide sequences claimed in patent US8945552 and likely identify XMab1 and XMab2 as candidates for vanucizumab [1]. |
| No information available. |
Summary of Clinical Use  |
| Phase 1 clinical trials are underway in patients with advanced/metastatic solid tumors either as monotherapy or combined with RO7009789, an anti-CD40 investigational antibody. Phase 2 trial NCT02141295 is evaluating vanucizumab plus FOLFOX (oxaliplatin with 5-fluorouracil and folinic acid chemotherapy) against FOLFOX plus bevacizumab (an anti-VEGFA, anti-angiogenic antibody) in patients with untreated metastatic colorectal cancer. |
| Mechanism Of Action and Pharmacodynamic Effects |
| ANGPT2 and VEGFA are both proangiogenic mediators. Blocking the activity of both of these factors at the same time is predicted to provide enhanced anti-angiogenic activity compared to anti-VEGFA therapy alone. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02141295 | A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer | Phase 2 Interventional | Hoffmann-La Roche | ||
